# Will the FDA approve a seasonal influenza vaccine for the 2025-2026 flu season before October 1, 2025? (QID: 38824)

- Type: binary

- URL: https://www.metaculus.com/questions/38824/

- Classifier: health | strategic=False (score=0.00)

## Research (summary)

CALIBRATION GUIDANCE (auto-generated weekly):
BINARY CALIBRATION
- No resolved binary questions (with pre-resolution forecasts) yet.
- Advice: keep using base rates + small evidence-weighted updates; avoid big swings.

MULTIPLE-CHOICE CALIBRATION (Top-1)
- No resolved MCQ questions (with pre-resolution forecasts) yet.

NUMERIC CALIBRATION (PIT-lite + CRPS)
- No resolved numeric questions (with pre-resolution forecasts) yet.
- When numeric results exist, we’ll check p10/p50/p90 coverage and CRPS.

General takeaway: apply **small** nudges only where gaps are consistent with decent sample sizes (≥10).
— end calibration —

### Reference class & base rates
- **Annual FDA Approval of Seasonal Influenza Vaccines**: Historically, the FDA has approved seasonal flu vaccines annually since 1973, suggesting a base rate of near 100%.
- **FDA Meeting Cancellations**: Rare, but when they occur, they can delay processes; no specific base rate available.

### Recent developments (timeline bullets)
- [2025-02-26] ↓ — FDA canceled VRBPAC meeting, potentially delaying strain selection and approval.
- [2025-01-XX] ↓ — U.S. withdrawal from WHO may disrupt international collaboration on strain selection.

### Mechanisms & drivers (causal levers)
- **FDA Process Consistency**: Historically robust, large positive driver.
- **International Collaboration**: Withdrawal from WHO, moderate negative driver.
- **Political Influence**: Executive orders affecting health policy, moderate negative driver.
- **Public Health Prioritization**: Shifts in focus, small to moderate driver.
- **Manufacturing Timelines**: Production schedules, moderate driver.

### Differences vs. the base rate (what’s unusual now)
- **Canceled VRBPAC Meeting**: Unprecedented disruption in the approval timeline.
- **U.S. Withdrawal from WHO**: Alters international strain selection collaboration.
- **Political Climate**: Increased political influence on health policy decisions.
- **Communication Barriers**: Reduced interaction with global health bodies.

### Bayesian update sketch (for the statistician)
- **Prior**: Near certainty of approval based on historical consistency (equivalent n = high).
- **Evidence mapping**:
  - ↓ Large: Canceled VRBPAC meeting.
  - ↓ Moderate: U.S. withdrawal from WHO.
  - ↓ Moderate: Political influence on health policy.
  - ↑ Small: Historical consistency of FDA processes.
- **Net effect**: Posterior should move down moderately due to significant disruptions.

### Indicators to watch (leading signals; next weeks/months)
- **UP indicators**:
  - Rescheduling of VRBPAC meeting.
  - New international collaborations for strain selection.
  - Positive statements from FDA officials.
- **DOWN indicators**:
  - Continued lack of communication with WHO.
  - Further political interventions in health policy.
  - Delays in vaccine manufacturing announcements.

### Caveats & pitfalls
- **Uncertainty in Political Decisions**: Rapid policy changes can occur.
- **Data Gaps**: Limited information on internal FDA deliberations.
- **Deception Risks**: Potential misinformation in politically charged environment.
- **Regime Changes**: New policies may alter health priorities.
- **Definitional Gotchas**: Ensure clarity on what constitutes "approval."

Final Research Summary: The likelihood of FDA approval for the 2025-2026 flu vaccine before October 1, 2025, is lower than usual due to the canceled VRBPAC meeting and U.S. withdrawal from WHO, despite historical consistency in approvals.

### Sources (autofetched)
- Game Recap: Eagles 20, Chiefs 17 | September 14, 2025 | NFL Regular Season Week 2 (philadelphiaeagles.com) — https://www.philadelphiaeagles.com/news/eagles-vs-chiefs-game-recap-september-14-2025-nfl-week-2
- Bears Continue Impressive Start To Season (calbears.com) — https://calbears.com/news/2025/9/14/mens-water-polo-bears-continues-impressive-start-to-season.aspx
- Buffs Trample Pioneers in Seventh Sweep of Season (cubuffs.com) — https://cubuffs.com/news/2025/9/14/volleyball-buffs-trample-pioneers-in-seventh-sweep-of-season
- Men’s Tennis Starts Fall Season at River Forest Collegiate Invitational (niuhuskies.com) — https://niuhuskies.com/news/2025/9/14/mens-tennis-mens-tennis-starts-fall-season-at-river-forest-collegiate-invitational.aspx
- Buckeyes Head to Inverness Club for Second Tournament of the Season (ohiostatebuckeyes.com) — https://ohiostatebuckeyes.com/news/2025/9/14/womens-golf-buckeyes-head-to-inverness-club-for-second-tournament-of-the-season
- Women's Golf Opens Season With Second Place at Batchelder Match Play (athletics.bowdoin.edu) — https://athletics.bowdoin.edu/news/2025/9/14/womens-golf-opens-season-with-second-place-at-batchelder-match-play.aspx
- Skol! Norwegian Podium Sweep as Casper Stornes becomes 2025 IRONMAN World Champion, earning his title on debut, in Nice, France (ironman.com) — https://www.ironman.com/news/skol-norwegian-podium-sweep-casper-stornes-becomes-2025-ironman-world-champion-earning-his
- All-Star Second Team: Loyd, Osman, Avdija, Markkanen, Jokic (fiba.basketball) — https://www.fiba.basketball/en/events/fiba-eurobasket-2025/news/all-star-second-team-loyd-osman-avdija-markkanen-jokic

## Per-model

- **OpenRouter-Default** ok=True time=16098ms cost=$10.9450 parsed=0.75

  - Raw output (excerpt):

    1. **Base Rate (Prior) Selection**
       - The historical base rate for the FDA approving seasonal influenza vaccines is near 100%, given the uninterrupted annual approval process since 1973. This suggests a very high prior probability for approval, close to 100%.
    
    2. **Comparison to Base Case**
       - Similarities: The FDA has a long-standing process for approving flu vaccines, which typically follows a consistent timeline.
       - Differences: The cancellation of the VRBPAC meeting and the U.S. withdrawal from the WHO are significant deviations from the norm. These differences introduce uncertainty into the approval process, which historically has been very stable.
    
    3. **Evidence Evaluation (Likelihoods)**
       - Canceled VRBPAC Meeting: This is a significant negative indicator, as it disrupts the usual timeline for strain selection and approval. The likelihood of this happening if the vaccine is approved (P(E | H)) is low compared to if it is not approved (P(E | ~H)), suggesting a likelihood ratio < 1.
       - U.S. Withdrawal from WHO: This reduces international collaboration, which is important for strain selection. Again, this is more likely if the vaccine is not approved, suggesting a likelihood ratio < 1.
       - Historical Consistency: The FDA's track record of approvals is a positive indicator, with a likelihood ratio > 1, but its impact is moderated by the current disruptions.
    
    4. **Bayesian Updating (Posterior Probability)**
       - Prior odds: Very high, close to 100% probability.
       - Likelihood ratios: The negative evidence (canceled meeting, WHO withdrawal) suggests a downward adjustment.
       - Posterior odds: Prior odds × Likelihood ratio (net effect of evidence).
       - Given the significant negative evidence, the posterior probability should be adjusted downward, but not drastically due to the strong historical base rate.
    
    5. **Red Team Thinking**
       - Overconfidence Risk: The historical base rate is very high, but current disruptions are unprecedented, suggesting a need for caution.
       - Alternative Scenarios: If the VRBPAC meeting is rescheduled or new collaborations are formed, the probability could increase.
       - Best Alternative Forecast: A more pessimistic view might suggest a lower probability if further political interventions occur.
    
    6. **Final Forecast**
       - Considering the strong historical base rate but significant current disruptions, a moderate downward adjustment is warranted. The final probability reflects both the historical consistency and the impact of recent negative evidence.
    
    Final: 75%

## Ensembles (with research)

- main=0.7084 | no_gtmc1=0.7084 | uniform=0.7084 | simple=0.7500

## Ablation (no research)

- main=0.7903 | uniform=0.7903 | simple=0.8500
